The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Long-Term Safety of Spironolactone in Acne: Results of an 8-Year Followup Study
Abstract
Background: Spironolactone has been used for over 20 years as an antiandrogen in the treatment of acne and hirsutism. No long-term studies of the safety of spironolactone used in this manner have been published. We present a study of the long-term safety and tolerance of spironolactone in 91 women with acne who were followed for up to 8 years. Methods: A survey questionnaire was sent to 210 patients, and a comparison chart review of all patients to whom the survey was sent was made. Results: Ninety-one completed surveys were analyzed, comprising 506 person-years of followup and 200 person-years of spironolactone exposure. Mean treatment length was 28.5 months (range = 0.5–122 months). During the 8-year followup period, there were no cases of serious illness attributable to spironolactone use. Side effects were present in 59% and resulted in cessation of the drug in 15%. Diuretic effect and menstrual irregularities were the most common adverse effects. Conclusions: After 200 person-years of exposure to spironolactone and 506 person-years of followup over 8 years, no serious illnesses thought to be attributed to spironolactone were reported. The long-term use of spironolactone in the treatment of acne in women appears to be safe. Side effects, however, are common, although not usually a cause for stopping the drug.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Common side effects also include diuresis, breast tenderness, breast enlargement, gynecomastia, fatigue, headache, and dizziness.234”
From Guidelines of care for the management of acne vulgaris (2024) · cites this paper as [234]
Citations
Cites
Zouboulis, C. C., Xia, L., Akamatsu, H., Seltmann, H., Fritsch, M., Hornemann, S., Rühl, R., Chen, W., Nau, H., & Orfanos, C. E. (1998) · Dermatology · doi:10.1159/000017861 · Cited by 219
Oral spironolactone improves acne vulgaris and reduces sebum excretion
GOODFELLOW, A., ALAGHBAND-ZADEH, J., CARTER, G., CREAM, J. J., HOLLAND, S., SCULLY, J., & WISE, P. (1984) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1984.tb04045.x · Cited by 172
Initial Screening for Carcinogenicity of Commonly Used Drugs23
FRIEDMAN, G. D., & Ury, H. K. (1980) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/65.4.723 · Cited by 148
Shaw, J. C. (2000) · Journal of the American Academy of Dermatology · doi:10.1067/mjd.2000.105557 · Cited by 134
Self-citationSpironolactone in dermatologic therapy
Shaw, J. C. (1991) · Journal of the American Academy of Dermatology · doi:10.1016/0190-9622(91)70034-y · Cited by 101
Self-citationHughes, B. R., & Cunliffe, W. J. (1988) · British Journal of Dermatology · doi:10.1111/j.1365-2133.1988.tb02571.x · Cited by 70
NONESTROGENIC DRUGS AND BREAST CANCER
Danielson, D. A., Jick, H., Hunter, J. R., et al. (1982) · American Journal of Epidemiology · doi:10.1093/oxfordjournals.aje.a113416 · Cited by 60
Research works printed but not linked: 3
- Lee O, 2000, Cochrane Database Syst Rev, 2, CD000194
- Loube SD, 1975, Breast cancer associated with administration of Spironolactone [letter], 1, 1428
- Barker DJP, 1987, J Drug Dev, 1, 22
Cited by
Guidelines of care for the management of acne vulgaris
Zaenglein, A. L., Pathy, A. L., Schlosser, B. J., Alikhan, A., Baldwin, H. E., Berson, D. S., Bowe, W. P., Graber, E. M., Harper, J. C., Kang, S., et al. (2016) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2015.12.037 · Cited by 1,597
Guidelines of care for the management of acne vulgaris
Reynolds, R. V., Yeung, H., Cheng, C. E., Cook-Bolden, F., Desai, S. R., Druby, K. M., Freeman, E. E., Keri, J. E., Stein Gold, L. F., Tan, J. K. L., et al. (2024) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2023.12.017 · Cited by 518
Haider, A. (2004) · JAMA · doi:10.1001/jama.292.6.726 · Cited by 273
James, W. D. (2005) · New England Journal of Medicine · doi:10.1056/nejmcp033487 · Cited by 269
Oral spironolactone for acne vulgaris in adult females: a hybrid systematic review
Layton, A. M., Eady, E. A., Whitehouse, H., Del Rosso, J. Q., Fedorowicz, Z., & van Zuuren, E. J. (2017) · American Journal of Clinical Dermatology · doi:10.1007/s40257-016-0245-x · Cited by 126
Metadata
- Authors
- Shaw, J. C., & White, L. E.
- Affiliations
- University of Toronto (CA)
- Venue
- Journal of Cutaneous Medicine and Surgery
- Publisher
- SAGE Publications
- Published
- 2002-11
- Volume
- 6
- Issue
- 6
- Pages
- 541-545
- ISSN
- 1203-4754 (ISSN-L)
- 1615-7109
- OpenAlex
- W2050783070
- Cited by
- 86
- References
- 7
- Citations by year
- 2025: 5 · 2024: 3 · 2023: 3 · 2022: 8 · 2021: 3 · 2020: 5 · 2019: 6 · 2018: 2 · 2017: 9 · 2016: 4 · 2015: 6 · 2014: 3 · 2013: 4 · 2012: 4
- FWCI
- 3.25
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
- Locations
- Journal of Cutaneous Medicine and Surgery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Dermatology › Acne and Rosacea Treatments and Effects
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Dermatology › Dermatologic Treatments and Research
- Keywords
- spironolactone, acne, long-term drug safety, adverse drug reactions, antiandrogen therapy, women, diuretic effect, menstrual irregularity, drug tolerance
- MeSH terms
- Acne Vulgaris, Mineralocorticoid Receptor Antagonists, Data Collection, Diuresis, Female, Follow-Up Studies, Humans, Menstruation Disturbances, Surveys and Questionnaires, Safety, Spironolactone, Time Factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-Term Safety of Spironolactone in Acne: Results of an 8-Year Followup Study. https://app.cochat.ai/papers/10.1177/120347540200600604
- The paper
- Shaw, J. C., & White, L. E. (2002). Long-Term Safety of Spironolactone in Acne: Results of an 8-Year Followup Study. Journal of Cutaneous Medicine and Surgery. https://doi.org/10.1177/120347540200600604
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
